BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
6/26/2026 9:50:22 AM | Browse: 0 | Download: 0
 |
Received |
|
2025-12-08 06:11 |
|
Peer-Review Started |
|
2025-12-08 10:06 |
|
First Decision by Editorial Office Director |
|
2026-02-06 10:20 |
|
Return for Revision |
|
2026-02-06 10:20 |
|
Revised |
|
2026-02-08 21:35 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2026-03-31 02:35 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2026-03-31 08:51 |
|
Articles in Press |
|
2026-03-31 08:51 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2026-06-15 11:01 |
|
Publish the Manuscript Online |
|
2026-06-26 09:50 |
| ISSN |
1948-5182 (online) |
| Open Access |
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Copyright |
©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Correspondence |
| Article Title |
Letter to the Editor: Steatotic liver disease in chronic hepatitis C - a marker of systemic risk, not direct-acting antiviral treatment failure
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Abdo Imad El Tawil and Claudia Alexandra Pontes Ivantes |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Abdo Imad El Tawil, Principal Investigator, Researcher, Department of Medical Research, Faculdade Evangélica Mackenzie do Paraná, Rua Padre Anchieta 2770, Curitiba 80730-000, Paraná, Brazil. abdoieltawil@gmail.com |
| Key Words |
Chronic hepatitis C; Direct-acting antiviral; Genotype 3; Liver cirrhosis; Steatotic liver disease; Liver fibrosis; Metabolic disfunction |
| Core Tip |
This letter discusses the real-world findings of Janczura et al, who evaluated the impact of steatotic liver disease on chronic hepatitis C virus infection in the era of direct-acting antivirals. Their work highlights how metabolic dysfunction, aging, and genotype-specific characteristics contribute to persistent liver risk despite viral cure. By emphasizing the role of noninvasive steatosis assessment in identifying high-risk patients and guiding long-term monitoring, this correspondence reinforces the clinical relevance of steatotic liver disease in shaping the prognosis and follow-up strategies for individuals with current or past hepatitis C virus infection. |
| Publish Date |
2026-06-26 09:50 |
| Citation |
El Tawil AI, Ivantes CAP. Letter to the Editor: Steatotic liver disease in chronic hepatitis C - a marker of systemic risk, not direct-acting antiviral treatment failure. World J Hepatol 2026; 18(6): 117018
|
| URL |
https://www.wjgnet.com/1948-5182/full/v18/i6/117018.htm |
| DOI |
https://doi.org/10.4254/wjh.117018 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
